PL401130A1 - High-dose dietary supplements containing active substances having a physiological effect in the form of effervescent tablets, with high stability, for preparation of solutions or suspensions, and processes for their preparation - Google Patents
High-dose dietary supplements containing active substances having a physiological effect in the form of effervescent tablets, with high stability, for preparation of solutions or suspensions, and processes for their preparationInfo
- Publication number
- PL401130A1 PL401130A1 PL401130A PL40113012A PL401130A1 PL 401130 A1 PL401130 A1 PL 401130A1 PL 401130 A PL401130 A PL 401130A PL 40113012 A PL40113012 A PL 40113012A PL 401130 A1 PL401130 A1 PL 401130A1
- Authority
- PL
- Poland
- Prior art keywords
- weight
- preparation
- substances
- active substances
- effervescent
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Przedmiotem wynalazku są wysokodawkowe suplementy diety zawierające substancje aktywne o działaniu fizjologicznym w formie tabletek musujących, o podwyższonej stabilności, do sporządzania roztworów lub zawiesin oraz sposób ich wytwarzania. W zależności od przeznaczenia tych suplementów w swych składach recepturowych zawierają co najmniej jedną substancję aktywną, co najmniej dwie substancje musujące, w zależności od rodzaju substancji aktywnych: solubilizator i/lub powłokę dojelitową lub powłokę maskującą smak, substancje wiążące i słodzące oraz aromat smakowy lub tylko co najmniej jedną substancję aktywną, substancje musujące, substancje smakowe, substancje wiążące i słodzące, przy czym tabletki te składają się z dwóch warstw o różnych ich składach recepturowych wybranych spośród ich składów całościowych. W szczególności suplementy te w swym składzie recepturowym zawierają: - 0,006-56,89% wagowych substancji aktywnych - 7,55-54,85% wagowych substancji musujących - 0,06-8,05% wagowych substancji wiążących 0,94-1,85% wagowych substancji smakowych - 0,02-0,05% wagowych substancji słodzących, a ponadto w zależności od pełnionej funkcji tego suplementu w organizmie może on zawierać dodatkowo: - 0,0009-0,30% wagowych solubilizatora - 0,008-0,198% wagowych powłoki dojelitowej, lub - 0,001-0,003% wagowych substancji maskującej smak.The subject of the invention are high-dose dietary supplements containing active substances with a physiological effect in the form of effervescent tablets with increased stability, for the preparation of solutions or suspensions, and the method of their production. Depending on the purpose of these supplements, their formulations contain at least one active substance, at least two effervescent substances, depending on the type of active substances: solubilizer and/or enteric coating or taste masking coating, binders and sweeteners and flavor aroma or only at least one active substance, effervescent substances, flavoring substances, binders and sweeteners, wherein said tablets consist of two layers with their different formulations selected from their overall compositions. In particular, these supplements in their recipe composition contain: - 0.006-56.89% by weight of active substances - 7.55-54.85% by weight of effervescent substances - 0.06-8.05% by weight of binders 0.94-1, 85% by weight of flavorings - 0.02-0.05% by weight of sweeteners, and in addition, depending on the function of this supplement in the body, it may additionally contain: - 0.0009-0.30% by weight of solubilizer - 0.008-0.198% % by weight of an enteric coating, or - 0.001-0.003% by weight of a taste masker.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL401130A PL235837B1 (en) | 2012-10-10 | 2012-10-10 | High-dose dietary supplements containing active substances having a physiological effect in the form of effervescent tablets, with high stability, for preparation of solutions or suspensions, and processes for their preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL401130A PL235837B1 (en) | 2012-10-10 | 2012-10-10 | High-dose dietary supplements containing active substances having a physiological effect in the form of effervescent tablets, with high stability, for preparation of solutions or suspensions, and processes for their preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL401130A1 true PL401130A1 (en) | 2014-04-14 |
| PL235837B1 PL235837B1 (en) | 2020-11-02 |
Family
ID=50442169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL401130A PL235837B1 (en) | 2012-10-10 | 2012-10-10 | High-dose dietary supplements containing active substances having a physiological effect in the form of effervescent tablets, with high stability, for preparation of solutions or suspensions, and processes for their preparation |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL235837B1 (en) |
-
2012
- 2012-10-10 PL PL401130A patent/PL235837B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL235837B1 (en) | 2020-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011116963A3 (en) | Lipid nanoparticle capsules | |
| MY149601A (en) | Masking the taste of powders | |
| MX344787B (en) | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders. | |
| Athira et al. | Flavonoids, the emerging dietary supplement against cisplatin-induced nephrotoxicity | |
| WO2011106493A3 (en) | Oral care compositions comprising magnolia bark extract or a synthetic analog thereof | |
| WO2014153160A3 (en) | METHOD OF ENHANCING THE BIODISTRIBUTION AND TISSUE TARGETING PROPERTIES OF THERAPEUTIC CeO2 PARTICLES VIA NANO-ENCAPSULATION AND COATING | |
| MX2015012199A (en) | Liposomal cisplatin compositions for cancer therapy. | |
| CY1118461T1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING AROMATOLOGY INGREDIENTS | |
| WO2011059292A3 (en) | Aloe vera sprout concentrate or extract having superior skin cell growth promotion, antioxidant, and anti-allergy effects | |
| ECSP10010164A (en) | DRY POWDER FORMULATIONS THAT INCLUDE DERIVATIVES OF ASCORBIC ACID | |
| WO2011093815A3 (en) | Pharmaceutical compositions comprising formoterol and mometasone | |
| WO2011093818A3 (en) | Pharmaceutical compositions comprising salmeterol and fluticasone | |
| WO2013170086A3 (en) | Formulations for the delivery of active ingredients | |
| WO2013100718A3 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases or asthma, containing lagerstroemia ovalifolia extract or fraction thereof as active ingredient | |
| PL401130A1 (en) | High-dose dietary supplements containing active substances having a physiological effect in the form of effervescent tablets, with high stability, for preparation of solutions or suspensions, and processes for their preparation | |
| WO2011141113A3 (en) | Combination of vitamin k and nicotinamide | |
| WO2017021974A3 (en) | Synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts | |
| WO2011093812A3 (en) | Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form | |
| WO2011013086A3 (en) | Pharmaceutical, cosmetic or dietetic composition for skin bleaching | |
| RU2416932C1 (en) | Functional food product with anti-flammatory properties againts digestive tract diseases | |
| TR201000619A2 (en) | Pharmaceutical composition in dry powder form comprising tiotropium and mometasone. | |
| PH12020500147A1 (en) | Compositions and methods for the treatment and prevention of cognitive decline and preservation of neuronal function | |
| WO2020018049A3 (en) | Lipid nanoparticles loaded with ceranib-2 as anticancer agents | |
| UA92445C2 (en) | Agent for immune status correction in children | |
| WO2010086736A3 (en) | Use of the combination of resveratrol with cysteine and derivatives thereof |